Hims & Hers to Acquire Australian Telehealth Startup Eucalyptus for A$1.6bn

Why It Matters

The structure delays cash to investors and staff, exposing them to legal and market risk, while the outcome will shape future exit expectations for Australia’s startup ecosystem.

Key Takeaways

• A$1.6bn sale includes 40% cash upfront.
• Earn‑outs tied to revenue and EBITDA through 2028.
• Employees receive half of cash now, rest later.
• Investors get ~18% upfront, remainder over 18 months.
• Hims & Hers faces Novo Nordisk lawsuit and FDA probe.

Pulse Analysis

The Eucalyptus‑Hims & Hers transaction is a textbook example of a staggered acquisition. While the headline A$1.6 billion price tag suggests an instant windfall, the deal delivers only US$240 million in cash at signing, split between investors and key employees. The remaining US$710 million is contingent on performance milestones, with a further US$200 million earn‑out tied to revenue and EBITDA targets through 2028. This structure keeps senior talent locked in, but it also means that most shareholders must wait years before realizing any upside.

Complicating the payout timeline are Hims & Hers’ ongoing legal battles. A three‑month partnership with Novo Nordisk collapsed amid accusations of illegal Wegovy sales, and the Danish drugmaker has since sued the company for patent infringement. Simultaneously, the U.S. FDA has opened a crackdown on non‑approved GLP‑1 compounds, casting a shadow over Hims & Hers’ core business model. These regulatory headwinds threaten the acquirer’s stock price and cash flow, especially since up to 60% of the deferred consideration may be paid in HIMS shares, whose value could be volatile amid the lawsuits.

From a broader perspective, the deal underscores the challenges of M&A in the health‑tech sector. Historically, 50‑70% of mergers fail to deliver promised synergies, and many acquirers overpay. For Australian venture capitalists, the Eucalyptus exit offers a rare liquidity event, but the protracted payment schedule and exposure to Hims & Hers’ legal risks temper the celebration. Success would validate the region’s ability to produce high‑value exits, while a shortfall could reinforce investor wariness about patient capital strategies in emerging markets.

Deal Summary

Hims & Hers Health (NYSE: HIMS) announced the acquisition of Australian telehealth startup Eucalyptus for an estimated A$1.6 billion (≈US$1.15 billion). The deal includes an initial cash payment of US$240 million (40% of the price) with the balance to be paid over 18 months and via earn‑outs, pending regulatory clearance. The transaction was announced in February 2026 and reported on March 2 2026.